Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients-Reference-Cited by-同舟云学术

Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients

Published:2012-01-26 Issue:18 Volume:118 Page:4471-4477
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Faderl Stefan,Ravandi Farhad,Huang Xuelin,Wang Xuemei,Jabbour Elias,Garcia-Manero Guillermo,Kadia Tapan,Ferrajoli Alessandra,Konopleva Marina,Borthakur Gautam,Burger Jan,Feliu Jennie,Kantarjian Hagop M.

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.27429/fullpdf

Reference18 articles.

1. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia;Kantarjian;Blood,2010

2. When a gold standard is made of tin;Schiller;Blood,2010

3. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers;Kantarjian;J Clin Oncol,2003

4. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors;Kantarjian;J Clin Oncol,2010

5. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy;Burnett;J Clin Oncol,2010

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients with TP53-Mutated Acute Myeloid Leukemia Receiving Intensive Induction Therapy Have Superior Outcomes Due to a Higher Rate of Salvage Therapy: A Single Institution, Retrospective Study;Cancers;2024-08-07

2. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML;Blood Advances;2023-06-30

3. Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia;Cancer;2023-01-30

4. A phase 3 trial of azacitidine versus a semi‐intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia;Cancer;2021-02-24

5. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?;Leukemia;2020-10-19